A single‐centre analysis of a biosimilar switching programme for adalimumab in inflammatory bowel disease
Switching to biosimilar adalimumab did not affect disease control or quality of life. 25% of patients developed new side effects, particularly those with high levels of health anxiety. Significant cost savings were achieved.
Authors
- Anna Hobbins (ORCID: https://orcid.org/0000-0002-5532-3830)
- Brian E. McGuire (ORCID: https://orcid.org/0000-0002-3540-6639)
- Linda Duane
- Laurence John Egan (ORCID: https://orcid.org/0000-0002-0142-6340)
- John Ferguson (ORCID: https://orcid.org/0000-0001-8475-398X)
- Louise Rabbitt (ORCID: https://orcid.org/0000-0001-9676-036X)
- Patrick Gillespie
- Áine Keogh
Institutions
- Ollscoil na Gaillimhe – University of Galway (IE)
- University Hospital Galway (IE)
Publication Details
- Journal
- British Journal of Clinical Pharmacology
- Published
- 2025-04-29
- DOI
- https://doi.org/10.1002/bcp.70086
- Citations
- 1
- Primary Topic
- Biosimilars and Bioanalytical Methods
- Type
- article
- Field-Weighted Citation Impact
- 0.80
Funders
- Canadian Institute for Theoretical Astrophysics
- Wellcome Trust
- Health Service Executive